Daré Bioscience, Inc.
DARE
$1.85
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10,412.24% | -103.04% | -100.62% | -99.08% | -99.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10,412.24% | -103.04% | -100.62% | -99.08% | -99.65% |
| Cost of Revenue | -22.67% | -90.81% | -90.82% | -90.83% | -84.50% |
| Gross Profit | 53.26% | 89.82% | 89.56% | 89.78% | 82.24% |
| SG&A Expenses | -4.29% | -9.22% | -18.99% | -21.78% | -23.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.84% | -30.12% | -37.61% | -29.36% | -30.07% |
| Operating Income | 42.21% | 24.16% | 30.92% | 22.44% | 23.71% |
| Income Before Tax | -230.55% | -384.47% | -158.33% | 94.19% | 86.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -230.55% | -384.47% | -158.33% | 94.19% | 86.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.55% | -384.47% | -158.33% | 94.19% | 86.56% |
| EBIT | 42.21% | 24.16% | 30.92% | 22.44% | 23.71% |
| EBITDA | 49.09% | 28.82% | 33.18% | 23.01% | 23.75% |
| EPS Basic | -161.76% | -271.97% | -106.91% | 94.68% | 87.68% |
| Normalized Basic EPS | -161.65% | -292.79% | -112.41% | 94.64% | 87.59% |
| EPS Diluted | -172.21% | -259.64% | -103.59% | 94.22% | 87.27% |
| Normalized Diluted EPS | -155.79% | -283.62% | -110.03% | 94.33% | 87.31% |
| Average Basic Shares Outstanding | 33.98% | 17.74% | 7.94% | 10.72% | 14.14% |
| Average Diluted Shares Outstanding | 33.72% | 17.51% | 7.71% | 10.93% | 14.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |